-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Outlines Phase 3 Timeline For PrimeC In ALS, Updates Canadian Regulatory Pathway, Highlights Partnership Talks With A Global Pharmaceutical Company; Says "We Have No Immediate Plans For Additional Capital Raising, We Maintain Strong Relationships With The Investment Community And Will Evaluate Strategic Opportunities As They Arise To Support Our Needs And Long-term Growth Objectives."

Benzinga·04/24/2025 13:12:30
Listen to the news

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company

CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer Alon Ben-Noon. The letter provides an update on the company's ongoing partnership discussions, regulatory and commercial pathway for PrimeC in ALS, clinical progress, and financial outlook. The full text of the letter is included below.

Financial Outlook

Our financial strategy continues to focus on maximizing shareholder value while ensuring adequate resources to advance our clinical programs. The potential strategic partnership is structured to significantly strengthen our financial position through upfront capital and funding for our Phase 3 program.

While we have no immediate plans for additional capital raising, we maintain strong relationships with the investment community and will evaluate strategic opportunities as they arise to support our needs and long-term growth objectives.